Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF developed using 3SBio’s proprietary CLF2 platform.

辉瑞公司（纽约证券交易所代码：PFE）今天宣布与三生制药（01530.HK）达成一项全球（不包括中国）许可协议，根据该协议，辉瑞获得三生制药开发的SSGJ-707的独家开发、生产和商业化权利。SSGJ-707是一种靶向PD-1和VEGF的双特异性抗体，采用三生制药专有的CLF2平台开发。

This agreement solidifies Pfizer at the forefront of innovative cancer research and further enhances the company’s robust oncology pipeline..

该协议巩固了辉瑞在创新癌症研究领域的前沿地位，并进一步增强了公司强大的肿瘤学研发管线。

“We are excited to contribute our significant expertise and resources to advance rapidly the development of the SSGJ-707 program including novel combination strategies across a number of our major tumor areas of focus,” said Chris Boshoff, M.D., Ph.D., Chief Scientific Officer and President, Research & Development, Pfizer.

“我们很高兴能够贡献我们的重大专业知识和资源，以加快推进SSGJ-707项目的发展，包括在多个我们重点关注的肿瘤领域中的新型组合策略，”辉瑞公司首席科学官兼研发总裁Chris Boshoff博士表示。

“This is an important candidate that combines two key targets in a promising class of medicines, complementing our antibody-drug conjugate portfolio and further demonstrates our commitment to advancing pioneering science to deliver transformative cancer medicines and new hope to people living with cancer.”.

“这是一个重要的候选药物，它结合了两类关键靶点，属于前景广阔的药物类别，补充了我们的抗体药物偶联物组合，进一步证明了我们致力于推进前沿科学，为癌症患者提供变革性药物和新希望的决心。”

SSGJ-707 is currently undergoing several clinical trials in China for non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and gynecological tumors. Positive interim Phase 2 results evaluating the safety and efficacy of SSGJ-707 as monotherapy in patients with advanced NSCLC were recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

SSGJ-707目前正在中国进行多项针对非小细胞肺癌（NSCLC）、转移性结直肠癌和妇科肿瘤的临床试验。近期，在美国临床肿瘤学会（ASCO）年会上公布了评估SSGJ-707作为单药治疗晚期非小细胞肺癌患者的安全性和有效性的二期临床试验中期积极结果。

Pfizer plans to manufacture drug substance for SSGJ-707 in Sanford, North Carolina, and drug product in McPherson, Kansas. The clinical development plan for SSGJ-707 moving forward will include trial sites across the U.S. and rest of world with priority to the Phase 3 global development plan for NSCLC and other solid tumors.

辉瑞计划在北卡罗来纳州的桑福德生产SSGJ-707的药物原料，并在堪萨斯州的麦克弗森生产药物制剂。SSGJ-707的临床开发计划将继续推进，包括在美国和世界其他地区的试验地点，优先考虑针对非小细胞肺癌（NSCLC）和其他实体瘤的III期全球开发计划。

The first Phase 3 global studies will initiate enrollment in the U.S..

第一阶段的全球第三期研究将开始在美国招募参与者。

Under the terms of the agreement, 3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio. Additionally, the agreement provides Pfizer the option to extend the license to include exclusive development and commercialization rights to SSGJ-707 in China.

根据协议条款，三生制药将获得12.5亿美元的付款。辉瑞还将对三生制药进行1亿美元的股权投资。此外，该协议授予辉瑞选择权，可将许可范围扩展至包括SSGJ-707在中国的独家开发和商业化权利。

In exchange for the exclusive rights in China, Pfizer will pay 3SBio up to $150 million in option payments. For additional background on the licensing deal, please read the announcement press release .

作为交换，辉瑞将为获得中国市场的独家权利向三生制药支付高达1.5亿美元的选择权款项。要了解更多关于此许可交易的背景信息，请阅读公告新闻稿。

About Pfizer Oncology

关于辉瑞肿瘤学

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, including other immune-oncology biologics.

在辉瑞肿瘤学，我们正处于癌症治疗新时代的前沿。我们行业领先的资产组合和广泛的研发管线包括三种核心作用机制，从多个角度攻击癌症，包括小分子、抗体药物偶联物 (ADC)、双特异性抗体，以及其他免疫肿瘤学生物制品。

We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives..

我们专注于在一些全球最常见的癌症领域提供变革性的治疗方法，包括乳腺癌、泌尿生殖系统癌症、血液肿瘤学以及胸部癌症（包括肺癌）。在科学的驱动下，我们致力于加速突破，以帮助癌症患者过上更好、更长寿的生活。

About Pfizer: Breakthroughs That Change Patients’ Lives

关于辉瑞：改变患者生活的突破性进展

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

在辉瑞，我们运用科学和全球资源，为人们带来能够延长生命并显著改善生活的疗法。我们努力在医疗保健产品的研发、开发和生产过程中，为质量、安全性和价值设定标准，包括创新药物和疫苗。

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

每天，辉瑞的同事都在发达市场和新兴市场工作，以推进对当今最令人恐惧的疾病的健康、预防、治疗和治愈方法。作为全球首屈一指的创新生物制药公司之一，我们与医疗保健提供者、政府和当地社区合作，支持并扩大全球获得可靠、负担得起的医疗保健的机会。

For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at .

175 年来，我们一直努力为所有依赖我们的人带来改变。我们会定期在网站上发布可能对投资者重要的信息。